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day in 1882 when Professor Robert Koch announced his discovery
of the microbial aetiology of TB, Mycobacterium tuberculosis (M. tb).
One hundred and thirty three years later, despite an effective cure
available for the past half century, TB continues to plague
humankind and remains one of the most common causes of death
from an infectious disease worldwide.
The latest WHO annual Global TB report estimates that in 2013,
there were 9 million people who developed TB of which an
estimated 1.2 million (14%) were people living with HIV.1 An
ominous increase is being seen globally in the number of new cases
of Multi-Drug Resistant TB (MDR-TB) and Extensively Drug-
Resistant TB (XDR-TB) with an estimated 480,000 new cases of
MDR-TB globally in 2013.2 World TB Day 2015 gives us an
opportunity to reﬂect on the trials and tribulations of global TB
control efforts, and to raise public and political awareness that TB
today remains a ‘global emergency’, is responsible for 1.5 million
deaths each year globally, and that MDR-TB and XDR-TB in Europe,
Asia and southern Africa are now major threats to global health
security. To commemorate World TB Day on March 24th 2015, we
have compiled this special issue of the International Journal of
Infectious Diseases, which comprises 32 articles (commentaries,
viewpoints, and reviews) on a range of TB subject areas written
by a global authorship.
Despite efﬁcacy in reducing the incidence of disseminated and
more severe forms of TB in children, the age old Bacille-Calmette-
Gue´rin (BCG) vaccine has shown limited effectiveness in preven-
tion of active disease in older children, adolescents and adults.3
Progress is being made in the search for more effective, universally
applicable TB vaccines.4 Chris DaCosta et al.5 review vaccines which
are currently under evaluation in phase II clinical trials and other
candidates in the pre-clinical development pipeline. These include
novel recombinant mycobacterial-based priming vaccines, various
booster vaccines (adjuvanted subunit, viral-vectored, whole cell),
immunotherapeutic vaccines and Mycobacterium vaccae. Axelsson-
Robertson et al.6 show that a broad CD8+ T-cell response towards
individual M. tuberculosis epitopes is required, in contrast to what
has been described for viral (e.g. EBV, CMV or HIV) infections.7
Zumla et al.8 suggest the potential use of host-directed immune-
modulatory interventions, like repurposed drugs and cellular
therapy using the patient’s own bone-marrow derived Mesenchy-
mal Stromal Cells (MSCs) as adjunct host-directed therapies,
together with anti-TB drugs, for TB pericarditis and TB meningitis.http://dx.doi.org/10.1016/j.ijid.2015.01.009
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Parida et al.9 review adjunct T-cell based immune-interventions in
infectious diseases and particularly cellular host-directed therapy,10
using MSCs, to balance damaging inﬂammation, limit bacterial
proliferation and restore anti-M.tb directed immune responses for
improving treatment outcomes in patients with MDR-/XDR-TB. Bell
and colleagues11 review paradoxical reactions and TB associated
immune reconstitution inﬂammatory syndrome (TB-IRIS).
Zumla and colleagues12 highlight the unique opportunities
presented by the launch of the second programme (2015-2024) of
the European & Developing countries Clinical Trials Partnership
(EDCTP), a 1.4 billion Euros initiative established jointly between
EU and African countries, for research and capacity building to
tackle diseases of poverty including TB. Maitra et al.13 provide their
insights into the use of moxiﬂoxacin, linezolid and clofazimine,
tebipenem with clavulanic acid, or repurposed drugs such as
thioridazine and chlorpromazine for treatment of MDR-/XDR TB.
Lessem et al.14 provide patient, provider and community perspec-
tives on access to new TB drugs bedaquiline and delamanid, and
the existing drug linezolid for treatment of MDR-TB. They remind
us that access to these medicines even in industrialized countries
remains a signiﬁcant challenge because of restrictions on licensing
and high cost, suggesting that improved access through drug
donation programs are urgently needed. Madansein and collea-
gues15 inform us that surgery is increasingly being explored as a
treatment option particularly in MDR-TB and XDR-TB with
associated lung destruction and poor results despite adequate
drug treatment. Open thoracotomy is gradually being replaced
with Video Assisted Thoracic Surgery (VATS), which is performed
using smaller incisions. Whilst Brown et al. highlight the paucity of
available data on health status and quality of life in both treated
and untreated TB.16
M.tb bacilli employ various strategies to overcome antibiotic
pressure such as differentiating into various physiological states
ranging from drug sensitive actively dividing states to slow or
non-replicating drug tolerant ones.17,18 Slowly growing bacteria are
less susceptible to drugs because of the reduced metabolic activity,
and it is important to investigate the way that different M.tb
subpopulations are formed during infection, and the in vitro and in
vivo models used for understanding is reviewed by Evangelopoulos
et al.19 A recent meta-analysis of 9,153 patients with MDR-TB
showed that the proportion of MDR-TB cases treated successfully
remains sub-optimal, with 62% treatment success, 7% treatment
failure or relapse, 9% death and 17% default reported.20 In theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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achieved treatment success, 22% failed treatment or relapsed,
whereas 15% died and 16% defaulted.21
Early diagnosis of MDR-TB and XDR-TB is the key to treatment
success and control of epidemic spread. McNerney et al.22 review
the rapid TB diagnostics portfolio and indicate that whilst the use
of rapid, molecular diagnosis was seen as the key to earlier
diagnosis, evaluation studies indicate limited impact on detection
rates and patient survival, re-emphasizing the need for a rapid
point of care TB test. Skoura et al.23 review the usefulness of
imaging for diagnosis, locating pathology and monitoring response
to treatment. Chest radiography remains the mainstay and
cheapest imaging option for screening of parenchymal disease
in pulmonary TB. Computed tomography (CT), Positron Emission
Tomography (PET) and Magnetic Resonance Imaging (MRI) scans
are more sensitive in locating extra-pulmonary lesions, but are not
widely available in resource restricted settings.
The development of drug resistance was previously thought to
result mainly from poor treatment adherence, but as illustrated by
Marais et al., 24 in their review of the epidemic spread of MDR-TB in
Johannesburg, primary transmission now drives the epidemic
spread of drug resistant TB in some high incidence settings.24
Fonseca et al.’s25 review informs us that the selection of drug
resistant strains involve complicated resistance determinants
such as M.tb strain genetic background, compensatory mutations
that restore ‘‘ﬁtness’’, low-level changes in drug susceptibility
that may not be appreciated and variability in individual
pharmacokinetics. One strategy for optimizing treatment efﬁcacy
is therapeutic drug monitoring, which both ensure adequate
doses and monitor compliance and this is reviewed by Sotgui
et al.26 Craig and Zumla27 in their study of TB treatment in urban
risk groups in the United Kingdom highlight that compliance to
treatment in marginalized group pose particular challenges. The
growing problem of TB in prisoners and M.tb transmission in
prisons worldwide is reviewed by Dara et al.28 highlighting
speciﬁc difﬁculties in operational aspects of TB testing, manage-
ment and surveillance. Weak health systems contribute to the
growing burden of drug resistant TB. Jabeen et al.29 highlight
the contribution of poor regulatory policies and irresponsible
drug use.
The speciﬁc management problems posed by TB in pregnancy,
especially in high TB/HIV endemic areas, are reviewed by Bates
et al.30 TB in pregnancy and also congenital TB is more common
than previously assumed. Wejse et al.31 highlight that the risk of TB
is higher in HIV-1 infected individuals compared to HIV-2 infected,
and co-infection with both HIV-1 and HIV-2 did not increase the
risk of TB as compared to HIV-1 only. Negin et al.32 remind us that
we need to take more notice of TB in older people, since they
contribute a large and growing burden of disease and are more
likely to have extra-pulmonary and atypical forms of TB, both of
which are often more difﬁcult to diagnose than sputum smear-
positive pulmonary TB. Byrne et al.33 explore the association
between TB and chronic respiratory disease in a systematic review,
indicating that previous TB is a risk factor for chronic obstructive
lung disease (COPD), particularly in non-smokers, and contributes
a large fraction of population attributable COPD risk in TB
endemic areas.
The majority of TB transmission in the community and in
healthcare settings occurs well before the diagnosis of TB is made.
Healthcare workers (HCWs) worldwide have an increased risk of
developing TB. Von Delft and colleagues34 present an illuminating
account from personal experiences of health care workers who
contracted TB. Their viewpoint illustrates why it is important to
ensure that TB infection control measures are applied in all high-
risk settings so that healthcare facilities become known as places of
healing and are safe, and not places associated with death and sitesof contagion. The risk of TB transmission to health care workers
and clients using health care services should not be under-
estimated. However, fear of TB infection should not inﬂuence the
quality of patient care provided. This can only be adequately
addressed by education and proper containment facilities.
Wejse35 in his viewpoint on achieving TB elimination reminds
us that whilst extensively promoted, the efﬁcacy of directly
observed therapy (DOT) has not been shown to be superior to self-
administration. The DOT strategy also focus exclusively on
symptomatic TB patients, without attempting to reduce the pool
of latently infected people.36 Large scale population-based
preventive therapy to eliminate the huge reservoir of people with
latent TB infection is a possible path being explored, but rapid re-
infection remains a challenge in settings with uncontrolled
transmission. It will require carefully designed, randomized
controlled studies to establish its ‘‘real-life’’ impact. These studies
are difﬁcult to conduct, since they should exclude people with sub-
clinical or undiagnosed TB, and it is impossible to rule out
individuals harboring drug-resistant strains of M. tb.
In response to the alarming rates of drug resistant TB in
countries of the former Soviet Union, 53 Member States of WHO
European Region endorsed the ﬁve- year (2011-2016) Consolidat-
ed Action Plan to Prevent and Combat MDR-/XDR-TB in Europe.37
D’Ambroio and colleagues38 review the ERS-WHO Consortium,
which recommends that management of MDR-TB and XDR-TB
cases is supported by specialized teams. They highlight the need
for increased resources and the fact that current programs cover
only a fraction of patients in each country. Islam et al.39 review the
establishment of WHO regional Green Light Committees (rGLCs) to
provide decentralized and better contextualized guidance to
national PMDT (Programmatic Management of Drug resistant
TB) efforts, and relate the successes and challenges of the Western
Paciﬁc rGLC. In March 2014, the Western Paciﬁc Region also
established a taskforce to focus on TB in children and adoles-
cents.40 Graham et al.41 relate perspectives from the Asia-Paciﬁc
region and the experience of individual countries developing
national child TB action plans. Trinh et al.42 provide an overview of
the TB and HIV situation in the Asia-Paciﬁc region where HIV co-
infection is not regarded as a major driver of the TB epidemic. They
point out that 6.3% of TB cases tested were HIV-positive in
2013 which requires closer scrutiny, since HIV tests are only
selectively performed in TB patients.
Over the past 3 decades, HIV/AIDS has attracted enormous
investment in developing new drugs and decentralized models of
care to turn the tide. Malaria has also mobilized huge ﬁnancial
resources with the distribution of cheap and effective impregnated
bed nets, but investments into TB have sadly lagged behind!
The long incubation period, diagnostic difﬁculties and the long
treatment period all create obstacles for effective control. Vertical
programs are unlikely to be sufﬁcient to achieve ultimate TB
elimination without better integration into other health care
services, together with enhanced and sustained efforts. Wallstead
and Maeurer43 remind us that TB was highly endemic 150 years ago
in what are now low endemic countries in Western Europe, and
give the example of TB control efforts in the pre-chemotherapy
area in Sweden. Floe and colleagues44 show that even in low
incidence countries like Denmark, TB patients are characterized by
lower income and pose an economic burden on health services.
Since TB is primarily a disease of poor and disadvantaged
populations, and less likely to attract investment from funders
and donor countries, it requires sustained and high proﬁle
advocacy to remain on the political agenda, as exempliﬁed by a
review of the questions posted on TB in the United Kingdom
parliament by Matt Oliver and colleagues.45
WHO estimates that there are 3 million men, women and
children globally with active TB who are currently being missed by
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these three million people live in the world’s poorest countries, and
include the most vulnerable members of the community such as
displaced populations and homeless people, individuals with
immune-suppression, pregnant women, migrants, prisoners, drug
users and sex workers. To reach the three million we need to
aggressively scale up political, funder and governmental commit-
ment to ensure universal access to TB care for all.46 In 2014, the
World Health Assembly endorsed the ‘‘Global Strategy and Targets
for Tuberculosis Prevention, Care and Control’’47 which aim for the
elimination of TB as a public health threat by 2035. An ambitious
target, which can only be achieved if TB is made a priority by
governments and donors, backed up with increased investment
into bold new public health approaches.
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